Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | NMBR | P28336 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039638 | 0.93 | SIRT2 (0.43) | SIRT2CYP11B1CYP11B2NMBR | |
| SCHEMBL1039740 | 0.91 | SIRT2 (0.43) | SIRT2CYP11B1CYP11B2NMBR | |
| SCHEMBL1097103 | 0.88 | SIRT2 (0.42) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL8543176 | 0.84 | SIRT2 (0.40) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL5792879 | 0.83 | SIRT2 (0.47) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL7939506 | 0.82 | SIRT2 (0.40) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL10815629 | 0.82 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL3821641 | 0.81 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2NMBRENPP2 | |
| SCHEMBL1037377 | 0.80 | SIRT2 (0.33) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL4382643 | 0.78 | SIRT2 (0.54) | SIRT2CYP11B1CYP11B2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016109361-A2 | 3-FLUORO-BENZONITRILE INHIBITORS OF 11-BETA-HYDROXYLASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-2256118-B1 | Condensed imidazolo derivatives for the inhibition of aromatase and the treatment of aldosterone related diseases | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8835646-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| US-20130287789-A1 | Organic Compounds | NOVARTIS AG (CH) | 2013-10-31 | — | — | US | disclosed |
| EP-1919916-B1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-8314097-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20120277215-A1 | Organic Compounds | RECORDATI AG (CH) | 2012-11-01 | — | — | US | disclosed |
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| EP-2256118-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | PAPILLON JULIEN | 2010-09-23 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2029604-A2 | ALDOSTERONE SYNTHASE AND/OR 11BETA-HYDROXYLASE INHIBITORS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| EP-2001866-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| EP-1919916-A1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | Novartis AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007139992-A2 | ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007117982-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| WO-2007024945-A1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | NOVARTIS AG (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049616-A1 | Organic compounds | CYP19A1, CYP17A1, HSD17B11 | SIRT2 2715/4885CYP11B1 5/4885CYP11B2 14/4885 |
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | HSD11B1, HSD11B2, CYP11B1 | SIRT2 2223/4885CYP11B1 3/4885CYP11B2 4/4885 |
| US-20130287789-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | SIRT2 2715/4885CYP11B1 5/4885CYP11B2 14/4885 |
| US-20120277215-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | SIRT2 2715/4885CYP11B1 5/4885CYP11B2 14/4885 |
| US-20140357621-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | SIRT2 2715/4885CYP11B1 5/4885CYP11B2 14/4885 |
| US-20090182007-A1 | ORGANIC COMPOUNDS | REN, CYP17A1, HSD17B1 | SIRT2 3959/4885CYP11B1 12/4885CYP11B2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.